Abstracts tagged "Psoriatic arthritis"

Abstract Number: 2152 • ACR Convergence 2022
Depression and Other Neurological Disorders Are Associated with Biologic DMARD Failure in Psoriatic Arthritis
Nicoletta Luciano¹, Elisa Barone², Enrico Brunetta¹, Maria De Santis³, Angela Ceribelli⁴, Marta Caprioli⁵, Giacomo Maria Guidelli¹, Arianna Sonaglia¹, Daniela Renna⁶, Francesca Motta⁷, Natasa Isailovic⁷, Matteo Vecellio³ and Carlo Selmi⁸, ¹IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Rozzano, Italy, ²IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Rozzano (MI), Lombardia, Italy, ³Humanitas University, IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Pieve Emanuele, Italy, ⁴Humanitas Research Hospital, Humanitas University, Rozzano (MI) Italy, Borgo San Giacomo, Italy, ⁵IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Pavia, Italy, ⁶IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Milano, Italy, ⁷Humanitas University, IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Rozzano (MI), Italy, ⁸Humanitas University, IRCCS Humanitas Research Hospital, Rheumatology and Clinical Immunology, Rozzano, Italy
Background/Purpose: The management of patients with psoriasis and psoriatic artrhitis (PsA) has been recently enriched and has thus become more challenging by the wide armamentarium…
Abstract Number: 0311 • ACR Convergence 2022
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Zunsemetinib, an Investigational Oral MK2 Inhibitor, at 80 Mg and 120 Mg Twice Daily Dose Levels in Healthy Subjects
Ajay Aggarwal¹, David Burt², Laura Connelly², Joseph Monahan² and Jessea Lu², ¹Aclaris Therapeutics, Wellesley, MA, ²Aclaris Therapeutics, Inc., Wayne, PA
Background/Purpose: Zunsemetinib is an orally available potent and selective small molecule inhibitor of the p38α MAPK/MK2 signaling axis. Aclaris Therapeutics, Inc. is developing zunsemetinib for…
Abstract Number: 0583 • ACR Convergence 2022
Toll-Like Receptor Ligands Stimulated Monocyte-Derived Langerhans Cell-Like Dendritic Cells Induce Psoriasis-Related Molecules, IL-23 and Delta-Like-4
Rei Takahashi¹, Kohei Maeda¹, Toshihiro Tanioka¹ and Takeo Isozaki², ¹Division of Pathogenesis and Translational Medicine, Department of Clinical Pharmacy, Showa University School of Pharmacy, Tokyo, Japan, ²Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
Background/Purpose: Monocyte-derived Langerhans cell-like dendritic cells (Mo-LCs) are involved in epidermal disorders such as psoriasis in murine models. However, the roles of Mo-LCs in the…
Abstract Number: 1019 • ACR Convergence 2022
Association Between Stringent Clinical Measures of Disease Activity and Clinically Meaningful Improvements in Patient-Reported Outcomes in Psoriatic Arthritis: Results from KEEPsAKE 1 and 2 Clinical Trials
Alexis Ogdie¹, Joseph Merola², Roberto Ranza³, Ahmed Soliman⁴, Manish Mittal⁴, Byron Padilla⁵, Sandra Ciecinski⁶, Priscila Nakasato⁷ and Laure Gossec⁸, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Serviço de Reumatología, Universidade Federal de Uberlândia, Uberlândia, Brazil, ⁴AbbVie, Inc., North Chicago, IL, ⁵AbbVie, Inc., Waukegan, IL, ⁶AbbVie, Inc., Mettawa, IL, ⁷AbbVie Inc, Toronto, ON, Canada, ⁸Sorbonne Université, Paris, France
Background/Purpose: Assessment of disease activity in PsA patients is important to evaluate therapeutic response in clinical trials. Patient-reported outcomes (PROs) are evaluated to assess benefits…
Abstract Number: 1095 • ACR Convergence 2022
A20(Tnfaip3) in Keratinocytes Restricts an Early Antiviral Gene Program Associated with Psoriatic Skin and Joint Disease
Bahram Razani¹, Jared Liu¹, Ryan Tobias¹, Sugandh Kumar¹, Zhi-Ming Huang¹, Wilson Liao², Barbara Malynn³ and Averil Ma³, ¹Dept. of Dermatology, UCSF, San Francisco, ²Dept. of Dermatology, San Francisco, ³Division of Gastroenterology, UCSF, San Francisco
Background/Purpose: A20 (Tnfaip3) levels are reduced in psoriatic plaques and polymorphisms in the TNFAIP3 gene locus are associated with increased risk for both psoriasis and psoriatic…
Abstract Number: 1418 • ACR Convergence 2022
Change in Disease Activity and Occurrence of Adverse Events After Initiation of Etanercept in Pediatric Patients with Juvenile Psoriatic Arthritis in the CARRA Registry
Colleen Correll¹, Scott Stryker², David Collier³, Anne Dennos⁴, Stephen Balevic⁵, Thomas Phillips⁵ and Tim Beukelman⁶, ¹University of Minnesota, Minneapolis, MN, ²Amgen Inc., San Francisco, CA, ³Amgen Inc., Simi Valley, CA, ⁴Duke University, Durham, NC, ⁵Duke Clinical Research Institute, Durham, NC, ⁶Childhood Arthritis and Rheumatology Research Alliance (CARRA), Birmingham, AL
Background/Purpose: Juvenile psoriatic arthritis (JPsA) constitutes ~5% of juvenile idiopathic arthritis (JIA). Several therapeutics are available for JPsA; however, given the low JPsA incidence, important…
Abstract Number: 1505 • ACR Convergence 2022
Blue-collar Workers with Psoriatic Arthritis: Disease Activity, Work Disability and Response to Biologics
Nina Colla¹, Julia-Tatjana Maul², Burkhard Moeller³, Michael Nissen⁴, Nikhil Yawalkar⁵, Eleftherios Papagiannoulis⁶, Oliver Distler¹, Adrian Ciurea⁷ and Raphael Micheroli⁸, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²Department of Dermatology and Venereology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ³Inselspital - University Hospital Bern, Bern, Switzerland, ⁴Hopitaux Universitaires de Genève, Geneva, Switzerland, ⁵Department of Dermatology, University Hospital Inselspital Bern, Bern, Switzerland, ⁶Statistics Group, SCQM Foundation, Zurich, Switzerland., Zürich, ⁷University Hospital Zurich, Zürich, Switzerland, ⁸University Hospital Zurich, Department of Rheumatology, Zürich, Switzerland
Background/Purpose: Biomechanical stress is a possible trigger of inflammation in psoriatic arthritis (PsA). The influence of physically demanding occupations on this potential association has not…
Abstract Number: 1760 • ACR Convergence 2022
Diagnoses Rates in Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus Patients During COVID-19
W. Cliff Rutter, Will Cavers, Jean Park, Elisea Avalos-Reyes and Kjel Johnson, CVS Health, Lincoln, RI
Background/Purpose: COVID-19 is of particular concern to patients with autoimmune rheumatic diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and systemic lupus erythematosus (SLE).…
Abstract Number: 2119 • ACR Convergence 2022
Bimekizumab Treatment Results in Improvements in Fatigue and Pain in Biologic DMARD-Naïve or TNFi-IR Patients with Active Psoriatic Arthritis: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
M. Elaine Husni¹, Philip J Mease², Joseph Merola³, Frank Behrens⁴, Ennio Giulio Favalli⁵, Dennis McGonagle⁶, William Tillett⁷, Shigeyoshi Tsuji⁸, Barbara Ink⁹, Deepak Assudani⁹, Rajan Bajracharya⁹, Jason Coarse¹⁰, Jérémy Lambert¹¹ and Laure Gossec¹², ¹Cleveland Clinic, Cleveland, OH, ²Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ³Harvard Medical School, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ⁵University of Milan, ASST Gaetano Pini-CTO Institute, Milano, Italy, ⁶Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; National Institute for Health Research, Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁸Department of Orthopaedics and Rheumatology, Nippon Life Hospital, Osaka, Japan, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ¹¹UCB Pharma, Colombes, France, Irigny, France, ¹²Sorbonne Université, Paris, France
Background/Purpose: Patients with psoriatic arthritis (PsA) have identified fatigue and pain as important features relevant to their burden of disease.1 Bimekizumab (BKZ), a monoclonal IgG1…
Abstract Number: 2136 • ACR Convergence 2022
Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis: Achievement of Minimal Disease Activity and Its Components
Arthur Kavanaugh¹, Laura Coates², Joseph Merola³, Philip J Mease⁴, Miroslawa Nowak⁵, Subhashis Banerjee⁵, Lauren Hippeli⁵ and Tom Lehman⁵, ¹University of California San Diego, La Jolla, CA, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁵Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Tyrosine kinase 2 (TYK2) is an intracellular kinase in the Janus kinase (JAK) family that mediates the signaling of multiple cytokines, including those central…
Abstract Number: 2153 • ACR Convergence 2022
Key Differences Between US Rheumatologists’ and Dermatologists’ Management of Psoriatic Arthritis
Maxine Yarnall, Spherix Global Insights, Exton, PA
Background/Purpose: The last few years have seen the approval of many new agents for the treatment of psoriatic arthritis (PsA) and psoriasis (PSO), resulting in…
Abstract Number: 0377 • ACR Convergence 2022
Differences in Early-onset vs. Late-onset Psoriatic Arthritis: Data from the RESPONDIA and REGISPONSER Studies
Maria Angeles Puche Larrubia¹, lourdes Ladehesa-Pineda², María Dolores López Montilla², Raquel Granados³, Eduardo Collantes⁴ and Clementina Lopez-Medina⁵, ¹Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Granada, Spain, ²Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain, ³Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Córdoba, Spain, ⁴IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ⁵Reina Sofia University Hospital, Rheumatology Department, Jaén, Spain
Background/Purpose: The prevalence of late-onset Psoriatic Arthritis (PsA) is increasing in parallel with the progressive aging of the population. The elderly population presents a greater…
Abstract Number: 0699 • ACR Convergence 2022
Effectiveness by Disease Severity in Patients with Psoriatic Arthritis Treated with Apremilast in the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Alexis Ogdie¹, Jacqueline O'Brien², Wendi Malley², Elizabeth Kohl², Kate Orroth³, Yuri Klyachkin⁴, Myriam Cordey⁵ and Philip J Mease⁶, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²CorEvitas, LLC, Waltham, MA, ³Amgen, Manhattan Beach, CA, ⁴Amgen, Lexington, KY, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Clinical trials of the efficacy and safety of apremilast have shown a significant therapeutic effect on disease activity across clinically diverse PsA patients. Given…
Abstract Number: 1021 • ACR Convergence 2022
Depression as a Modulator of Patient Reported, but Not Physician Observed, Outcomes in Psoriatic Arthritis
Rebecca Haberman¹, Seungha Um², Sydney Catron¹, Eileen Lydon³, Malavika Attur², Andrea Neimann², Soumya Reddy⁴, Andrea Troxel¹, Samrachana Adhikari¹ and Jose Scher⁵, ¹NYU Langone Health, New York, NY, ²NYU Langone, New York, NY, ³New York University, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) is a complex immune-mediated disease. Beyond its deleterious effects in the skin and joints, PsA can lead to decreased quality of…
Abstract Number: 1096 • ACR Convergence 2022
IL-23 Induced Growth Differentiation Factor 15 Contributes to Trabecular Bone Loss, but Does Not Affect Skin, Gut or Joint Inflammation in Psoriatic Arthritis
Renée Van der Cruyssen¹, Djoere Gaublomme¹, Emilie Dumas¹, Carolien Vlieghe¹, Flore Stappers², Julie Coudenys¹, Tine Decruy¹, Lars Vereecke¹, Eric Gracey¹ and Dirk Elewaut³, ¹VIB-UGent Center for Inflammation Research, Ghent University, Belgium, Gent, Belgium, ²VIB-UGent Center for Inflammation Research, Ghent University, Ghent, Belgium, ³Department of Rheumatology, Ghent University Hospital, Belgium, VIB-UGent Center for Inflammation Research, Ghent University, Heusden, Belgium
Background/Purpose: IL-23 mediated inflammatory diseases such as psoriasis and psoriatic arthritis are associated with bone loss in addition to more classical features such as skin…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].